This Is MS Multiple Sclerosis Knowledge & Support Community

I posted this in http://www.thisisms.com/ftopict-13871.html But, anyway, An ok story with links to even complete stories in the end: http://www.fiercepharma.com/story/novartis-pill-poised-rattle-ms-market/2010-09-22 Those links being: - get the release from Novartis http://www.fiercepharma.com/press...

An ok story with links to even complete stories in the end: http://www.fiercepharma.com/story/novartis-pill-poised-rattle-ms-market/2010-09-22 Those links being: - get the release from Novartis http://www.fiercepharma.com/press_releases/novartis-gains-fda-approval-gilenya - find the Biogen statement...

Looks like FDA is fast tracking it.

<shortened url>

I am just wondering what the MRI lesion load difference between placebo and betaferon is in the two fingolimod studies. If my memory serves me right, that was where they had stronger results. In other words, back when Betaferon meds were going through their studies, researchers were targeting MRI le...

Oops, per your last question, I am not able to see the third study (I don't have a subscription). But, I thought that Betaferon was only very marginally helpful. I looked into it some years ago, so I don't remember all the details. However, the lack of effectiveness is one of the main reasons my wif...

ama, Don't worry, English was not my first language either and yours is very clear. This is the way I understand lesions, though, I could be wrong. Lesions disappear with time. A lesion is either an active inflammation in the brain or what used to be active and is in the process of "healing&quo...

I think you are making good points and it is bothering me also since you pointed it out. As I mentioned before, one possible explanation is that an event was more likely to be called a relapse in the Finglimod study. See below. For the Cladribine study, it says, "A relapse was defined as an inc...

I am not familiar with either protocol (though, I probably should be since my wife was in the fingolimod study). However, my only point is that studies are designed so that apple to apple comparison is made between the groups within the study. Differences between the studies can exist for a variety ...

I would guess that they had different criteria for study participants. For example if one study required one relapse within two years, while the other required two relapses within one year, one would expect placebo groups (as well as other groups) to be very different.

Not phenominal, but clearly positive. WASHINGTON, Feb 26 (Reuters) - A drug being developed by Acorda Therapeutics Inc (ACOR.O) helps some people with multiple sclerosis walk better, an important step in improving their quality of life, U.S. researchers said on Thursday. http://uk.reuters.com/articl...

Thank you! Good luck and I wish everything goes well for you.

Just remember that even though you may be helping others, the most important person is you. If you start feeling like too much of a guinea pig, or that your interests are not being put first, you can always opt out.

DM,

Good luck and keep us informed. As many others on this board, I believe that you are doing the right thing. It is for the common good.
Hopefully you'll never have another lesion and you'll never have progression. Watch out for yourself.

Wish you the best!!!

DM, nobody can tell you to do this or not to do it. However, (1) you'll get someone to monitor your disease (being a post middle age at diagnosis makes you a high risk for very fast disease progression. It is especially true if you are a male.), (2) you'll have a good chance of receiving an oral dru...

Agreed, just wanted to point out for the less statistically minded, the concept of looking for effectiveness of Campath alone cannot be solved for without extra assumptions. On Bob's original question about effectiveness of the combination, I don't believe there is any disagreement. It does look to ...

CureOrBust, I definitely wasn't trying to say anything about your neuro. I am sorry if it did sound that way. I think, given that they are in Australia, it is not very likely that they would know about a compound that may look promissing but is very tied to proximity to the processing lab. All I was...